Eli Lilly presented early data on brenipatide, a long-acting dual GIP/GLP-1 receptor agonist, as the company explores use beyond weight loss and type 2 diabetes. At Psych Congress 2026, Lilly reported Phase 1 multiple ascending dose findings in overweight or obese patients and healthy volunteers, emphasizing tolerability and gastrointestinal side-effect patterns. Lilly said brenipatide is already in Phase 3 trials for alcohol use disorder and major depressive disorder. The presentation signals how incretin platforms are being tested as multi-disease candidates, with trial design and safety monitoring central as programs move toward larger efficacy endpoints.